As of Friday close, Royalty Pharma plc’s (NASDAQ:RPRX) stock was up $0.99, moving up 2.54 percent to $39.94. The average number of shares traded per day over the past five days has been 2,546,480 shares. 2 times new highs have been achieved over the past 5 days, with a $0.22 gain in that time frame. In the last twenty days, the average volume was 2,601,530, while in the previous 50 days, it was 2,235,886.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, RPRX stock retreated -5.89%. Shares of the company fell to $37.07 on 05/10/22, the lowest level in the past month. A 52-week high of $47.10 was reached on 04/14/22 after having rallying from a 52-week low of $34.86. Since the beginning of this year, RPRX’s stock price has risen by 0.23% or $0.09, and marked a new high 6 times. However, the stock has declined by -15.20% since its 52-week high.
Royalty Pharma plc (RPRX) last reported insider trading activity 46 days ago on Mar 29. RIGGS RORY B, the Director of the company, disposed of 60,000 shares for $38.59 on Mar 29. It resulted in a $2,315,322 divestment by the insider. RIGGS RORY B sold 39,867 shares at an average price of $39.05 on Mar 21. The insider now owns 0 shares following the transaction. On Mar 18, Director RIGGS RORY B sold 129,222 shares at $39.55 apiece. The transaction was valued at $5,110,675.
Right now, Royalty Pharma plc (RPRX) has a P/E ratio of about 38.93. Besides these, the trailing price-to-sales (P/S) ratio of 10.91, the price-to-book (PB) ratio of 2.96.
The latest dividend of $0.19 per share was paid out, remained unchanged from last year’s $0.19. On Thursday January 6 2022, a $0.02 dividend increase was announced.
In the three months ended March 30, Royalty Pharma plc’s quick ratio stood at 22.00, while its current ratio was 22.00, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.70. In the year ended March 30, operating margins totaled 62.10%. Based on annual data, RPRX earned $858.75 million in gross profit and brought in $2.29 billion in revenue.
In Royalty Pharma plc’s quarter-end financial report for March 30, it reported total debt of $7.1 billion against cash and short-term investments of $549.02 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RPRX’s revenue fell -1.95% to $575.7 million during the quarter, while net income inched up to $562.05 million. While analysts expected Royalty Pharma plc to report $0.73 quarterly earnings, the actual figure was $0.6 per share, beating the consensus estimate by -17.80%. During the quarter, the company generated $230.73 million in EBITDA. The liabilities of Royalty Pharma plc were 7.24 billion at the end of its most recent quarter ended March 30, and its total debt was $7.1 billion. The value of shareholders’ equity is $607.18 million.
This quick technical analysis looks at Royalty Pharma plc’s (RPRX) price momentum. With a historical volatility rate of 47.61%, the RSI 9-day stood at 45.77% on 13 May.
With respect to its five-day moving average, the current Royalty Pharma plc price is up by +0.55% percent or $0.22. At present, RPRX shares trade -9.43% below its 20-day simple moving average and +3.96% percent above its 100-day simple moving average. However, the stock is currently trading approximately +3.74% above its SMA50 and +4.42% above its SMA200.
Stochastic coefficient K was 29.26% and Stochastic coefficient D was 19.19%, while ATR was 1.39. Given the Stochastic reading of 42.05% for the 14-day period, the RSI (14) reading has been calculated as 45.93%. As of today, the MACD Oscillator reading stands at -0.80, while the 14-day reading stands at -1.80.